Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London

CHAPEL HILL, N.C., Nov. 9, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the Jefferies 2012 Global Healthcare Conference in London at 4:20 p.m. GMT, Thursday, Nov. 15, 2012, at the Waldorf Hilton in London. Dr. Fernandes will provide an update of the company's two leading antibiotic clinical programs, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA™ for the chronic, oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.

About Cempra, Inc.

Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

Investor and Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
Robert.flamm@russopartnersllc.com

Andreas Marathovouniotis
Russo Partners, LLC
(212) 845-4235
Andreas.marathis@russopartnersllc.com

 

SOURCE Cempra, Inc.



RELATED LINKS
http://www.cempra.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.